310 related articles for article (PubMed ID: 36352372)
21. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues].
Peng LP; Gan WQ; Zheng YB; Chen YM; Liu J; Wu ZB; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2024 Mar; 32(3):193-200. PubMed ID: 38584099
[No Abstract] [Full Text] [Related]
23. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.
Ive P; MacLeod W; Mkumla N; Orrell C; Jentsch U; Wallis CL; Stevens W; Wood R; Sanne I; Bhattacharya D
PLoS One; 2013; 8(12):e74900. PubMed ID: 24324573
[TBL] [Abstract][Full Text] [Related]
24. Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B.
Harkisoen S; Arends JE; van den Hoek JA; Whelan J; van Erpecum KJ; Boland GJ; Hoepelman AI
Int J Infect Dis; 2014 Dec; 29():133-8. PubMed ID: 25449247
[TBL] [Abstract][Full Text] [Related]
25. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.
Xu J; Shi J; Wang YP; Lin Y; Chen YX; Lu J; Zeng X; Xie WF
Med Sci Monit; 2009 Jun; 15(6):CR274-9. PubMed ID: 19478697
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province].
Zhang BF; Cheng ML; Zhang Q; Zhao XK; Yu L; Yang J; Deng KS; Zhang LS; Wang J; Hu YX
Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):945-950. PubMed ID: 30669789
[No Abstract] [Full Text] [Related]
27. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
28. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
[TBL] [Abstract][Full Text] [Related]
30. Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.
Lin HC; Jeng WJ; Liu J; Pan MH; Lee MH; Batrla-Utermann R; Lu SN; Chen CF; Yang HI; Chen CJ
Aliment Pharmacol Ther; 2024 Apr; 59(8):993-1002. PubMed ID: 38410882
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
[TBL] [Abstract][Full Text] [Related]
32. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
34. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
37. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
[TBL] [Abstract][Full Text] [Related]
38. Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.
Brichler S; Nahon P; Zoulim F; Layese R; Bourcier V; Audureau E; Sutton A; Letouze E; Cagnot C; Marcellin P; Guyader D; Roulot D; Pol S; de Ledinghen V; Zarski JP; Calès P; Tran A; Peron JM; Mallat A; Riachi G; Grange JD; Blanc JF; Bacq Y; Ouzan D; Bronowicki JP; Mathurin P; Larrey D; Alric L; Attali P; Serfaty L; Pilette C; Bourlière M; Thabut D; Silvain C; Wartelle C; Zucman D; Christidis C; Roudot-Thoraval F; Ganne-Carrie N;
J Viral Hepat; 2019 Mar; 26(3):384-396. PubMed ID: 30380181
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B surface antigen in late hepatitis B infection.
Zeng DW; Zhu YY; Huang Q; Zhang JM; Wu YL; Dong J; Jiang JJ; Liu YR
J Med Virol; 2015 Mar; 87(3):380-7. PubMed ID: 25604455
[TBL] [Abstract][Full Text] [Related]
40. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]